Health Care & Life Sciences » Biotechnology | Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
33.65 M
Public Float
19.37 M
Syros Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.92
Market Cap
$280.15 M
Shares Outstanding
42.44 M
Public Float
21.53 M

Profile

Address
620 Memorial Drive
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.syros.com
Updated 07/08/2019
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines.

Financials

View All
Created with Highcharts 5.0.14Syros Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.13 43113 43129 81829 81847 74347 74354 01054 01062 27962 27920142015201620172018020k40k60k80k
Created with Highcharts 5.0.14Syros Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.003173173173171 1011 1012 0502 0502014201520162017201805001000150020002500

Peter Wirth
Chairman
Nancy A. Simonian
President, Chief Executive Officer & Director